Pulse of the Market: Wednesday’s 10 Top Performers

5. Sarepta Therapeutics Inc. (NASDAQ:SRPT)

Sarepta Therapeutics bounced back by 8.74 percent on Wednesday to close at $79.97 apiece as investors resorted to bargain-hunting following the prior day’s steep drop, caused by news that a young man succumbed to its treatment Elevidys.

In a news release, SRPT said the patient succumbed to acute liver failure after receiving the Sarepta Elevidys therapy, the only FDA-approved gene therapy for Duchenne muscular dystrophy.

While the risk has already been flagged on the Elevidys label, acute liver injuries leading to death have not been previously reported in clinical testing or real-world use of Elevidys.

SRPT said that the patient had a recent cytomegalovirus (CMV) infection which allegedly contributed to the death. The infection can damage the liver, leading to CMV hepatitis, which is fatal to those with weak immune systems.